Depression associated with low plasma amyloid-b peptide 42 (Ab42) leading to a high ratio of Ab40/Ab42, a biomarker of Alzheimer disease (AD), may represent a unique depression subtype. The relationship between low plasma Ab42 in depression and the major risk factor of AD, apolipoprotein E4 (ApoE4), is unknown. With the goal of clarifying this relationship, we analyzed 1060 homebound elders with ApoE characterization and depression status in a cross-sectional study. Plasma Ab40 and Ab42 were measured, and cognition were evaluated. In the absence of the ApoE4 allele, depressed subjects had lower plasma Ab42 [median (Q1, Q3): 17.1 (11.6, 27.8) vs. 20.2 (12.9, 32.9) pg/mL, P = 0.006], a higher Ab40/Ab42 ratio [median (Q1, Q3): 7.1 (4.6, 11.3) vs. 6.9 (3.4, 9.7), P = 0.03], and lower cognitive function (mean ± SD of Mini-Mental State Examination: 24.5 ± 3.1 vs. 25.5 ± 3.3, P<0.0001) than those without depression. In contrast, these relationships were not observed in the presence of ApoE4. Instead, regardless the depression status ApoE4 carriers had lower plasma Ab42 and a higher Ab40/Ab42 ratio than non-ApoE4 carriers. Using multivariate logistic regression, it was found that depression was not associated with ApoE4 allele, but with the interaction between plasma Ab42 and ApoE4 (odds ratio = 3.94, 95% confidence interval = 1.50, 10.33, P = 0.005), denoting low plasma Ab42 in the absence of ApoE4. Both ApoE4 carriers and non-ApoE4 carriers with depression had lower Ab42 and a higher Ab40/Ab42 ratio in plasma compared with non-ApoE4 carriers without depression in the homebound elderly. As a combination of low plasma Ab42 and high plasma Ab40 has been shown to increase the risk of AD in 2 large cohort studies, amyloidassociated depression shown in this study may suggest a risk factor of AD in the absence of ApoE4.
D epression is a clinical syndrome with multiple pathologies and etiologies, and prodromal depression of Alzheimer disease (AD) is one subtype of depression in the elderly. [1] [2] [3] Clinically, it is often seen that some depressed, elderly patients are diagnosed and treated for depression, and then longitudinally these patients develop cognitive decline and AD. Therefore, finding specific biomarkers to differentiate prodromal depression of AD from other depression subtypes is critical, especially when therapies targeting at the early stage of AD are currently under development.
Our recent study has shown that depressed elders without cardiovascular disease (CVD) have a lower concentration of plasma Ab42, a biomarker of AD, compared with depressed elders with CVD and those without depression in a homebound population. 4 In addition, we found that depression with a high plasma Ab40/Ab42 ratio, determined by both low Ab42 and high Ab40, is associated with poor memory in the same population. 5 Because 2 large cohort studies have shown that a high Ab40/Ab42 ratio in plasma increases the risk of developing AD, 6, 7 it is hypothesized that depression characterized by low Ab42 and a high Ab40/Ab42 ratio in plasma may represent prodromal depression of AD that is distinct from vascular depression. 8 We have termed it ''amyloid-associated depression.' ' The apolipoprotein E4 (ApoE4) allele is the major genetic risk factor of late-onset AD. 9 Some studies have shown that late life depression is not associated with ApoE4. 10, 11 However, among the elders aged 80 and older who have a much higher AD prevalence than those with a younger age, a relationship between ApoE4 and depression is observed, suggesting the existence of a prodromal depression of AD. 12, 13 ApoE4 is associated with higher amyloid plaque burden composed mainly by Ab42 in AD brains than those carrying ApoE2 and ApoE3, 14 probably through reduced clearance or accelerated aggregation of the peptide. Although the meaning of the relationship between depression and low concentration of Ab42 in plasma is unclear, plasma Ab42 declines significantly in the preclinical stage of AD. [15] [16] [17] [18] These studies suggest that reduced plasma Ab42 either plays a role in AD pathogenesis or is a biomarker predicting the onset of AD. As both ApoE4 and depression could be a prodromal stage of AD, we hypothesize that they may share some AD biomarkers, such as Ab in plasma. To investigate this possibility, we explored the relationship between plasma Ab42 and depression in those with and without the ApoE4 allele in a homebound elderly population.
MATERIALS AND METHODS

Study Population and Recruitment
We studied a group of 1060 subjects, all of whom had been characterized for ApoE and depression status from an ongoing, population-based study, the Nutrition, Aging, and Memory in the Elderly (NAME) study. Subjects included homebound elderly clients who were enrolled in 1 of 4 homecare agencies in the Boston area between 2003 and 2006. Elders aged 60 and older were invited to participate in the study. Anyone receiving homecare services was registered with one of these agencies if he/she lives in the city of Boston, had an annual income less than $18,890 and needed homecare service. All homebound elders aged 60 and older at each of the 4 agencies were invited to participate in the study. Eligibility for enrollment required that the participants spoke English, were physically able to participate in the study home visits, and had sufficient vision and hearing to read and hear the content of the neuropsychologic tests. Those with Mini-Mental State Examination r10 or verbal Intelligence Quotient <75 were not eligible to continue in the study. Of all eligible subjects, 66% enrolled in the study, and gave informed consent. Each subject participated in 3 home visits conducted by a research assistant, who drew fasting blood and collected data on depression and medical conditions. 19 
Measurements
ApoE Genotyping
A 244-bp fragment of the ApoE gene including the 2 polymorphic sites was amplified by polymerase chain reaction using a robotic Thermal Cycler (ABI 877, Perkin-Elmer/Applied Biosystems), using oligonucleotide primers F4 (5 0 -ACAGAATTCGCCCCGGCCTGGTAC AC-3 0 ) and F6 (5 0 -TAAGCTTGGCACGGCTGTCCA AGGA-3 0 ). The polymerase chain reaction products were digested with 5 U of Hha I and the fragments separated by electrophoresis on 8% polyacrylamide nondenaturing gel. The specific allelic fragments were: E2, E3, and E4. ApoE4 was defined by E4/4, E3/4, or E2/4. 20
Plasma Ab40 and Ab42
The blood samples were centrifuged immediately after the blood was drawn. The sandwich Ab enzyme-linked immunosorbent assay was used. Plates were coated with 2G3 (anti-Ab40) and 21F12 (anti-Ab42) antibodies overnight at 41C. Samples were then loaded and incubated overnight at 41C followed by incubation with a biotinylated monoclonal anti-N terminus Ab antibody (3D6B) for 2 hours. Finally, streptavidin-conjugated alkaline phosphatase (Promega) was added and incubated, and the signal was amplified by adding alkaline phosphatase fluorescent substrate (Promega), which was then measured. The lowest detection for both Ab peptides was 1.6 pg/mL in the standard curves with % coefficient of variation between 1.1 and 7.2. However, we used 3.1 pg/mL for both Ab 1 to 40 (2 samples) and 1 to 42 (10 samples) as a low cut-point. Ab samples were treated as the cut-points for comparison and regression if their levels were below the cut-point of detection. The samples with higher levels than the standard curve were repeated with dilutions for measurement. The intracorrelations with 2 other laboratories, which have published the results of the Ab measurement, 21, 22 showed R = 0.63 and 0.84 for Ab40, and R = 0.90 and 0.96 for Ab42.
Depression
Depressive symptoms were assessed by using the Center for Epidemiological Studies Depression Scale (CES-D) 23 ; a CES-D score of Z16 was used as the cutoff point for clinical depression. 24 This CES-D cutoff point had a sensitivity of 0.90 and a specificity of 0.83 for the Diagnostic and Statistical Manual of Mental Disorders-IV diagnosis of major depression by a board-certified psychiatrist in our study. Vascular depression was defined by a CES-D score Z16 and the presence of CVD.
Cognition
Research assistants, trained by a board certified neuropsychologist, administered the cognitive tests. The subjects were screened for severe cognitive impairment using the MMSE. 25 Those with MMSE <24 were defined for cognitive impairment and MMSE Z24 for intact cognition. Wechsler Memory Scale-III Logical Memory: 2 stories (A and B) were read aloud to the subject; the subject was then asked to repeat each story to assess immediate recall. After 30 minutes, the subject was asked to repeat both stories, which served as a measure of delayed recall.
CVD and Other Measurements
Subjects were classified as having CVD according to whether they had been previously informed by a doctor that they had congestive heart failure, coronary heart disease, angina pectoris, or a heart attack. Stroke history was recorded. Body mass index was measured and calculated as body mass (in kg) over the squared height (in m 2 ). Current hypertension was defined by the average of systolic blood pressure >140 mm Hg or diastolic blood pressure >90 mm Hg at 2 determinations. Renal function, which is associated with plasma Ab, 26 was assessed by measurements of serum creatinine.
Statistical Analysis
Statistical analysis was performed by using SAS (version 9.1). Normally distributed variables such as age were presented as mean ± SD and compared by using t test. Variables with skewed distributions (plasma Ab40 and Ab42) were presented as median (25th, 75th percentiles) and compared by using Wilcoxon rank sum test. 4 The w 2 test was used to compare proportions for binary end points. Both Ab40 (Log Ab40) and Ab42 (Log Ab42) were transformed to log 10 for multivariate regression owing to skewed distributions. Logistic regression was used to examine associations between depression (CES-D score Z16 vs. not) or intact cognition (MMSE score >24 vs. not) and Log Ab40 or Log Ab42 while adjusting for CVD, ApoE4, and other confounders of age, race, sex, school, and creatinine. The interactions between Log Ab42 and ApoE4 or between Log Ab42 and depression were applied to the logistic models. For all analyses, the 2-sided significant level of 0.05 was used. was 75.3 ± 8.4 years old, and 76% were female. It was multiethnic with 61% white, 35% African American, and 4% other ethnicities. Sixty-two percent of subjects had at least high school education. Depression, defined as a CES-D score Z16, was observed in 34% (365/1060) of the subjects. ApoE allele frequencies were ApoE2/2 = 15/1060 (1%); ApoE2/3 = 141/1060 (13%); ApoE2/4 = (32/1060 (3%); ApoE3/3 = 649/1060 (61%); ApoE3/4 = 204/1060 (19%); and ApoE4/4 = 19/1060 (2%). Overall, there were 255 subjects (24%) carrying at least 1 ApoE4 allele. Table 1 shows that other than ethnicity there were no differences in demographics in those with and without ApoE4 allele. There were a higher proportion of African American subjects in those carrying the ApoE4 allele than those without ApoE4 (49% vs. 33%, P<0.0001).
The rates of CVD and other vascular diseases of diabetes, stroke, and current hypertension were similar in those with and without ApoE4. Compared with non-ApoE4 carriers, ApoE4 carriers were found to have a comparable rate of depression (Table 1) or average CES-D score (mean ± SD: 13.3 ± 10.2 vs. 12.7 ± 10.2, P = 0.42). The proportions of those with cognitive impairment, as defined by MMSE score <24, were similar in those with and without the ApoE4 allele.
ApoE4 carriers had a lower concentration of plasma Ab42 (median: 17.4 vs. 19.2, P = 0.02) and a higher Ab40/Ab42 ratio (median: 7.9 vs. 6.9, P = 0.002) than non-ApoE4 carriers ( Table 2 ). In contrast, no differences in plasma Ab40 (median: 137.3 vs. 130.6, P = 0.34) and creatinine (mean ± SD: 1.3 ± 1.5 vs. 1.1 ± 0.8, P = 0.54) were found in those with and without ApoE4.
Depression and Plasma Ab Peptides Stratified by the ApoE4 Status
As depression is associated with low plasma Ab42, 4 in this study, we examined the effects of the ApoE4 allele on depression and plasma Ab peptides. Subjects were further divided into depression and no depression subgroups in both ApoE4 carriers and non-ApoE4 carriers ( Table 3 ). In the absence of the ApoE4 allele, depressed subjects had significantly lower plasma Ab42 [median (Q1, Q3): 17.1 (11.6, 27.8) vs. 20.2 (12.9, 32.9) pg/mL, P = 0.006] ( Fig. 1 ) and a higher Ab40/Ab42 ratio [median (Q1, Q3): 7.1 (4.6, 11.3) vs. 6.9 (3.4, 9.7), P = 0.03] than those without depression. When subjects with CVD were excluded from this subset of non-ApoE4 carriers, the differences in plasma Ab42 concentration (median: 15.7 vs. 20.7, P<0.0001) and Ab40/Ab42 ratio (median: 7.4 vs. 6.3, P = 0.002) in those with and without depression became more significant. In contrast, in the presence of ApoE4, no difference in plasma Ab42 was found in those with and without depression ( Fig. 1 ). Nevertheless, it was noted that ApoE4 carriers regardless of depression status and non-ApoE4 carriers with depression had lower plasma Ab42 compared with non-ApoE4 carriers without depression ( Figs. 1, 3) . No difference in plasma Ab40 was found between the subgroups with and without depression regardless of ApoE status (data not shown).
Additionally, in the absence of ApoE4, depressed subjects had significantly lower scores on MMSE (mean ± SD: 24.5 ± 3.1 vs. 25.5 ± 3.3, P<0.0001), and a greater number had cognitive impairment defined by a MMSE score lower than 24 (39% vs. 22%, P<0.0001) (Fig. 2 ) compared with those without depression. Furthermore, in the absence of ApoE4, depressed subjects had lower scores on logical memory (mean ± SD: 17.3 ± 9.7 vs. 19.4 ± 9.6, P = 0.002) than those without depression. In contrast, in the presence of ApoE4 no difference in MMSE (mean ± SD: 25.0 ± 3.8 vs. 25.0 ± 3.8, P = 0.88) was found in those with and without depression in this population (Fig. 1 ).
Analysis With Multivariate Regression
To further explore the relationship between depression and plasma Ab42 in the presence and absence of ApoE4, multivariate logistic regression was performed ( Table 4 ). As it is well documented that late life depression is highly related to vascular diseases, such as CVD, the analytic models were built on the basis of demographic variables in addition to vascular diseases to characterize any potential confounders, which might be expected. Low plasma Ab42 (odds ratio (OR) = 0.63, 95% confidence interval (CI) = 0.42, 0.94, P = 0.02) and CVD (OR = 1.79, 95% CI = 1.35, 2.37, P<0.0001) were independently associated with depression after adjusting for confounders of age, race, sex, diabetes, creatinine, and Ab40. There was no relationship between the ApoE4 allele and depression ( Table 4 : Model I). As the relationship between depression and plasma Ab42 was strengthened after stratification with ApoE4 ( Fig. 1) , we, therefore, analyzed the interaction between plasma Ab42 and ApoE4. This interaction, denoting low plasma Ab42 in the absence of ApoE4, was found to be positively associated with depression with OR = 3.94, 95% CI = 1.50, 10.33, P = 0.005 (Table 4 : Model II), and the relationship was further strengthened after adjusting for MMSE with OR = 4.65, 95% CI = 1.73, 12.5, P = 0.002 (Table 4 : Model III). The proportions of depressed African American subjects compared with the nondepressed subgroups were different in the presence (41% vs. 53%, P = 0.01) and absence (36% vs. 31%, P = 0.07) of ApoE4 (Table 3) .
Ethnicity, however, was not associated with depression (Table 4 ). Although in the absence of ApoE4 more depressed subjects had diabetes compared with those without depression, no difference was found in rates of diabetes between these subgroups in the presence of ApoE4 (Table 3) . Again, diabetes status was not found to be associated with depression in this study sample ( Table 4 ). The rates of stroke between those with and without depression were similar in the presence or absence of ApoE4, and stroke was not found to be associated with depression using multivariate regression analysis (data not shown).
DISCUSSION
ApoE4 is the major risk factor of AD, 9 and is associated with low level of Ab42 in cerebral spinal fluid even among the elderly with normal cognition. 27 Late life depression has also been shown to occur before AD. [1] [2] [3] Using a homebound elderly population, the subset of depressed non-ApoE4 carriers was found to have low plasma Ab42 and a high Ab40/Ab42 ratio, as would be expected had they been ApoE4 carriers (Tables 2, 4 ; Figs. 1, 3 ). And these depressed subjects had cognitive impairment, including poor memory (Figs. 2, 3) . As a high plasma Ab40/Ab42 ratio has been found to increase the risk of AD in 2 longitudinal studies, 6, 7 we hypothesize that amyloidassociated depression, characterized by low plasma Ab42 and high Ab40/Ab42 ratio, might represent another preclinical stage or a risk of AD in addition to ApoE4. We recently reported 4 that there are at least 2 separate depression subtypes in this homebound elderly population: (1) vascular depression, 8 which is linked with CVD and not necessarily associated with low plasma Ab42, 28 and (2) amyloid-associated depression, which is associated with low plasma Ab42. 28 In this study, we found that depression in the absence of ApoE4 was associated with low plasma Ab42 and high Ab40/Ab42 ratio (Fig. 1) . In the presence of the ApoE4 gene, however, low plasma Ab42 and high Ab40/Ab42 ratio were found regardless of depression status ( Table 2 and Fig. 1 ). Plasma Ab42 levels decline significantly before the onset of AD and in its early stages, 15 leading to a high plasma Ab40/Ab42 ratio, which significantly increases the risk of AD longitudinally. 6, 7 Depression may also precede AD. [29] [30] [31] [32] [33] Therefore, although ApoE4 might lead to AD regardless of depression status, amyloid-associated depression accompanied by a decline in plasma Ab42 may herald AD even in the absence of the ApoE4 allele.
Plasma Abeta42, depression and ApoE4
Cognition, depression and ApoE4
Studies have shown that plasma Ab peptides cannot be used to diagnose AD. 34, 35 Our findings in this study were consistent with these previous studies in that we did not find a relationship between cognition and plasma Ab42 alone in the homebound elderly (data not shown). We found, however, that cognitive impairment was associated with the cooccurrence of low plasma Ab42 and depression in the absence of ApoE4 (Fig. 2) , even after adjusting for confounders (data not shown). This result suggests that, despite its lack of usefulness in diagnosing the disease in its later stage, low plasma Ab42 might represent a prognostic biomarker indicating a preclinical stage or an early stage of AD, 6,7 especially in those who have depression. Low Ab42 in cerebral spinal fluid, a consensus diagnostic test for AD, 36 correlates with plasma Ab42 at the preclinical stage of AD, but this relationship disappears in the later stage of the disease. 37 Multiple etiologies of AD involving multiple pathways can result in the brain AD pathologies: Ab plaques and neurofibrillary tangles. ApoE4 is one major AD risk factor, and its role in AD pathogenesis is probably mediated through increased aggregation of Ab or impaired clearance of Ab in the brain (reviewed in Ref. 38) . It is not yet clear how late life depression influences the degenerative process of AD. A history of depression correlates with an increase in both amyloid plaques and neurofibrillary tangles in AD. 39 In contrast, approximately 80% of the depressed elderly do not develop AD after a 4-year follow-up. 3 This suggests that there are different subtypes of depression in the elderly including (1) early-onset depression; (2) poststroke depression 40 (5) comorbid depression in AD. In our study, after adjusting for MMSE the relationship between depression and plasma Ab42 in the absence of ApoE4 was strengthened (Table 4 : Model III), suggesting that different depression subtypes have different cognitive patterns and prognoses. As these depression subtypes may have different underlying pathologies, not all would be expected to be related to plasma Ab, or plasma Ab might bear upon the subtypes in different ways. The finding that depression associated with a high plasma Ab40/Ab42 ratio present with significant poorer memory compared with those with a low plasma Ab40/ Ab42 ratio argues that amyloid-associated depression is probably a preclinical stage of AD. 5 Our study did not find a difference in depression rates between those with and without ApoE4 ( Table 1 ). This result was consistent with previously published studies that showed that the ApoE4 allele does not increase the risk of late life depression. 10, 11 Other studies showed that in subjects aged 80 and older, a relationship between ApoE4 and depression is observed, 12, 13 probably suggesting a prodromal depression of AD. It is noted that the average age of our study sample was 75 years. Longitudinal studies have shown that ApoE4 increases the risk of cognitive decline in the elderly. [41] [42] [43] In our study, those non-ApoE4 carriers with depression had lower cognitive function compared with those who did not have depression (Fig. 2) . At cross-sectional level, those ApoE4 carriers tended to have more cognitive impairment than those non-ApoE4 carriers without depression, but did not reach the statistical significance.
Although our study and others 6, 7 have shown that low plasma Ab42 levels have a potential to be used as a prognostic biomarker of AD, another population study reports that high plasma Ab42 is associated with the risk of AD, but plasma Ab42 declines before the onset of the disease, 44 which could lead to low levels of plasma Ab42 at the prodromal stage. Unlike late-onset AD, both early-onset AD 45 and Down syndrome 46 present with high plasma Ab42 levels at the preclinical stage. One study shows that mild cognitive impairment patients have higher levels of plasma Ab42 than the controls only in women. 47 It is not yet known whether plasma Ab status is different at the preclinical stage of AD with and without depression. Importantly, despite that our assays in measurements of Ab40 versus Ab42 in plasma had high sensitivity and specificity, the field lacks standard assays for interlaboratory comparisons. Therefore, the complexity of plasma Ab 48,49 requires brain investigation and a longitudinal follow-up to validate amyloid-associated depression as a unique depression subtype. Other limitations of this study include: (1) the cross-sectional design prevents the study from exploring the possibility that depressed elderly with ApoE4 have shorter life spans and would therefore be less likely to be included in this study; (2) depression was based on the CES-D score rather than diagnostic and statistical manual of mental disorders-IV criteria, and we have no information about its onset and the course; and (3) we are unable to determine whether amyloid-associated depression is a precursor of AD without longitudinal data of the study. Nevertheless, our findings link amyloid-associated depression characterized by low plasma Ab42 and a high Ab40/42 ratio to cognitive impairment specifically in non-ApoE4 carriers. Prospective studies and brain investigations are needed to determine whether amyloid-associated depression is an independent risk factor for AD.
